无辅助征象的高血供LI-RADS 3类病灶的HCC风险
本研究回顾性纳入2013—2018年129例患者共166个动脉期高血供、无其他主要或辅助征象且小于2 cm的LI-RADS 3类观察。以类似已发表荟萃分析的复合参考标准判断HCC发生。结果显示10个(6.5%,95%CI 2.2–10.7%)观察进展为HCC,1年HCC率为3.0%(95%CI 0–6.1%),低于文献报告的总体LR-3人群。
要点
- 小于2 cm且仅动脉期高血供、无其他征象的LR-3病灶1年HCC率仅3.0%
- 病灶进展为HCC的中位时间为指数MRI后360天(范围90–947天)
- 此类LR-3病灶进展为HCC多表现为类别升至LR-5并伴生长
核心结论
- 无任何附加主要或辅助征象的小的高血供LR-3观察在1年时HCC发生率低于文献中整个LR-3人群的报告值
研究设计与样本
- 回顾性识别2013—2018年机构队列中MRI报告为高血供LR-3的连续病例
- 纳入标准为动脉期高血供、无附加主要或辅助征象且小于2 cm的观察
- 共纳入129例患者(平均年龄60±11岁,69例[53.5%]男性)166个LR-3观察
- HCC发生判断采用与已发表荟萃分析相似的复合参考标准
关键影像表现/征象
- 病灶表现为动脉期高血供,大小小于2 cm,无其他主要或辅助征象
诊断标准与关键数值
- 10个(6.5%,95%CI 2.2–10.7%)观察进展为HCC,依据为类别变为LR-5并出现生长
- 进展为HCC的中位时间为指数MRI后360天(范围90–947天)
- LR-3病灶1年HCC率为3.0%(95%CI 0–6.1%)
临床应用与阅片要点
- 对于小于2 cm、仅动脉期高血供且无其他征象的LR-3病灶,短期HCC风险较低,随访策略可结合这一结果综合判断
- 进展事件主要表现为随访中类别升至LR-5并伴生长,随访时重点关注类别变化与大小增长
局限性
- 本研究为单中心回顾性设计
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The Liver Imaging Reporting and Data System (LI-RADS) categorizes liver observations based on their risk for HCC, with LI-RADS 3 observations (LR-3s) having an intermediate probability. Studies have shown that approximately one-third of LR-3 observations develop into hepatocellular carcinoma (HCC), however, this is not observed in clinical practice. This study aimed to assess the HCC rate for hypervascular LR-3s.
METHODS: We retrospectively identified consecutive MRI reports from 2013 to 2018 with hypervascular LR-3s in our institutional cohort. Observations with arterial phase hyperenhancement, no additional major/ancillary features, and < 2 cm in size were included. Development of HCC was determined based on a composite reference standard similar to published meta-analysis.
RESULTS: 129 patients (mean age 60+/-11 years, 69 [53.5%] male) with 166 LR-3s observations were included. Ten (6.5%, 95% CI [2.2-10.7%]) observations developed into HCC based on change in category to LR-5 and growth in a median of 360 days (range 90-947) after index MRI. HCC rate for LR-3 was 3.0% at 1 year (95% CI [0-6.1%]).
CONCLUSION: We observed a lower rate of HCC development in small hypervascular LR-3s without any additional major/ancillary features at 1 year compared to the entire LR-3 population reported in literature.
引用
- Kadi, Kruse, Abedrabbo, et al. What is the risk of HCC in hypervascular LI-RADS 3 observations without ancillary features in routine clinical practice? Abdom Radiol (NY). 2026. PMID: 42360347. doi:10.1007/s00261-026-05613-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。